PolyPid to Showcase Q1 Financial Results and Innovations

Author: Thomas Cooper Updated: 04-29-2025 07:21 AM

PolyPid's Upcoming Financial Report

Petach Tikva, Israel - PolyPid Ltd. (NASDAQ: PYPD), a forward-thinking biopharmaceutical company dedicated to enhancing surgical outcomes, is preparing to announce its financial results for the first quarter of 2025. This all-important report will be released just before U.S. financial markets open on a Wednesday in mid-May. Following this release, PolyPid will host a conference call and a live webcast at 8:30 AM Eastern Time to discuss the details of its financials and provide an update on its ongoing operations.

Conference Call Details

For shareholders and interested parties wishing to participate, it’s recommended to register at least five minutes prior to the call. If you’re not planning to ask questions, you might find it more convenient to listen via the webcast instead. This format allows for broader access and engagement with the company’s updates.

About PolyPid Ltd.

Founded as a late-stage biopharmaceutical company, PolyPid Ltd. aims to make significant strides in the surgical field. Their innovative approach employs local administration of prolonged-release therapeutics through the proprietary PLEX technology. This advanced system allows for optimal drug delivery tailored to surgical needs, with controlled release over varying durations—spanning from a few days to several months.

Currently, PolyPid is spearheading its lead product candidate, D-PLEX100, which is in a critical Phase 3 clinical trial aimed at preventing infections in abdominal colorectal surgeries. Beyond this, PolyPid is also venturing into new territories with its OncoPLEX initiatives, focusing on solid tumors such as glioblastoma, which are in preclinical evaluation stages.

Company Contacts

For further inquiries and detailed information, the company's investors and those interested in more comprehensive queries can reach out via email. Ori Warshavsky, the Chief Operating Officer for the U.S., is readily available at 908-858-5995 or through the email address IR@Polypid.com. Investors can also connect with Brian Ritchie from LifeSci Advisors for related concerns at 212-915-2578 or at Britchie@lifesciadvisors.com.

Frequent FAQs

What are PolyPid's key product innovations?

PolyPid is focusing primarily on its D-PLEX100, aimed at preventing surgical infections, and OncoPLEX, targeting solid tumors like glioblastoma.

When will the Q1 results be released?

The financial results for the first quarter of 2025 will be announced on a Wednesday in mid-May, before the U.S. markets open.

How can investors access the conference call?

Investors can register for the conference call at least five minutes before the start time to participate or listen to the live webcast.

What is PolyPid's mission?

PolyPid aims to improve surgical outcomes through innovative drug delivery technologies, reducing risks associated with surgical procedures.

Where can I find more information about PolyPid?

Further details can be found on PolyPid's official website or through their social media channels on Twitter and LinkedIn.

About The Author

Hello, I'm Thomas Cooper, a financial expert and writer passionate about helping people understand and navigate the financial world. Having a solid financial background and a lot of experience, my area of expertise is simplifying difficult financial ideas into useful, understandable guidance. My goal with my writings and blog entries is to provide you the information and resources you need to make wise financial choices.

I am thrilled to contribute my ideas and engage with a lively investor community at Investors Hangout, where I recently joined the team. My mission is to make finance interesting and approachable so you may take charge of your financial future. I appreciate you coming along on this path to success and financial knowledge.

Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.